Tuberculosis I. The fight against tuberculosis has been mismanaged during seventy years, up till today. How did the mycobacterial community lose the war against TB
Main Article Content
Abstract
This review exposes the discovery of microbes by Leeuwenhoek in 1677, stresses the importance of food availability for the spread of tuberculosis, and underlines the absence of food security up till today for about 9.2% of the population, which favors the tuberculosis endemic. It describes the discovery of tuberculosis bacilli by Koch and the neglect by the physicians of plant drugs in favor of chemotherapy and surgery. The fight against tuberculosis was trusted by the World Health Organization in 1950, whose prime duty it was at that time to jugulate Tuberculosis. It was granted exemption of judicial pursuits to reach this goal. It immediately exploited this baffling privilege to abuse it and favor national commercial interests. The “Bacillle Calmette-Guérin” vaccine proposed by the French Ministry of Health in 1950 was known to be inadequately attenuated as early as 1927, was known by the World Health Organization to favor the spread of tuberculosis and nevertheless was promoted by the World Health Organization as a sole vaccine to combat the spread of tuberculosis. On the contrary, it reactivated dormant tuberculosis and leprosy cases and favored the endemic of both tuberculosis and leprosy. Despite this evidence, the vaccine was not removed but its deficiencies were steadfastly denied or else ignored. Alternative approaches, namely immunotherapy based on mycobacterium vaccae and a plant extract based on uleine, a substance known to stimulate the immune defenses of an organism infected by the tuberculosis pathogen, were combatted by the Belgian Ministry of Health and ignored by the World Health Organization. The chemotherapy was restricted during decennia to only four, plus streptomycin, which favored the rise of drug-resistant tuberculosis strains. New drugs proposed in addition to the four in use already, are expensive and riven by so many side effects, including death, that they are massively rejected by the patients. A blood test able to spot immune-depressed subjects and verify the efficacy of chemotherapy was banned by the World Health Organization and vigorously defamed by the Indian Ministry of Health. A review of the means used by the World Health Organization to fight the tuberculous endemy shows that these means are inadequate for the purpose, were so from the beginning of the fight, and were rarely to never amended in later times to become more efficacious.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. R. Maes. Is Tuberculosis our new challenge? Lambert academic publishing 2016. https://drive.google.com/file/d/1tSNKSNqTTZMTQfeDyktfSYc1sWORPg4G/view?usp=sharing
2. Farnia P. Preventive food complements and preventive TB diagnostic.2023 https://docs.google.com/document/d/12H-tpxwqof0Kq-hxx2BVxf5Sr2caommw/edit?usp=sharing&ouid=106232283876325533470&rtpof=true&sd=true
3. Cornwall J. Tuberculosis: a clinical problem of international importance Lancet 1997;349: 660- 661.
https://drive.google.com/file/d/1dXhpqBWp-pLeiLNQNKYfwmDvdRlvbN3-/view?usp=sharing (Only page 1).
4. Lignières J. Contribution à l'étude des qualités pathogènes du vaccin BCG contre la tuberculose. Bull. Acad. Méd. 1927.
5. Ferru M. La faillite du BCG. Témoignages d’hier et d'aujourd'hui. Chronique d'une faillite annoncée. 1995 France, 95210 Saint Gratien, B.P. 7.
6. Quiquandon H. Douze balles pour un veto. Ed. Agriculture et vie. 1978. Tome II page 18.
7. Grosset J. La tuberculose en France : état des lieux. Impact Médecin Quotidien. 1994 ; jeudi 17 novembre.
8. Frimodt-Moller J. Observations on the protective effect of BCG in a South Indian rural population. Bull. Int. Union TB, 48, 40-49 (1978) in Clinical Tuberculosis, 1994; P.O. Davies Eds (Chapman and Hall medical.
9. Tardieu M.et al. Tuberculous meningitis due to BCG in two previously healthy children. Lancet 1988 ;27 :440-441
10. Grosset J. Schwoebel V. Surveillance active de la méningite tuberculeuse en France en 1990. Bull Epidémiol Hebd. 1991 ;48, 209-210.
11. Bagghaie N. Masjedi M.R, Velayati A.A. Accuracy of BCG vaccination in prevention of tuberculous meningitis. 30th IUATLD World conference, 1999; Madrid, PS 30, 413-PD.
12. Wade H. BCG-induced activations. Int. J. Leprosy. 1960; 28: 179-181
13. Muliyil J. Effect of BCG on the risk of leprosy in an endemic area: a case-control study. Int. J. Leprosy. 1991; 59: 229-236.
14. Nguyen V, Abel L, Dinh Lap V, et al. Protective effect of BCG against leprosy and its subtypes: a case-control study in Southern Vietnam. Int. J. Leprosy. 1994; 62: 532-538.
15. Bagshawe. A, Scott G.C, Russell D.A, et al. BCG vaccination in leprosy: final results of the trial in Karimui, Papua New Guinea, 1963-1979. WHO Bulletin OMS. 1989; 67: 389-399.
16. Tripathy S.P. Fifteen years follow up of the Indian BCG prevention trial. XXVth World Conference of the International Union against TB, Singapore 1986. in Clinical Tuberculosis 1994; P.O. Davies Eds (Chapman and Hall medical.
17. Comstock G. The international Tuberculosis Campaign: a Pioneering Venture in Mass Vaccination and Research. Clin. Inf. Dis. 1994; 19: 528-540 .
18. Larsson L.O, Magnusson M, Skoogh B.E. et al. Sensitivity to sensitins and tuberculin in Swedish children. IV. The influence of BCG-vaccination. Eur. Respir. J. 1992; 5: 584-58.
19. Sousa A.O, Salem J.I, Lee F.K. et al. An epidemic of tuberculosis with a high rate of tuberculin anergy among a population previously unexposed to tuberculosis, the Yanomami Indians of the Brazilian Amazon. Proc Natl Acad Sci U S A. 1997; Nov 25; 94 (24): 13227-13232.
20. Nardell. E.A. Beyond four drugs. Public health policy and the treatment of the individual patient with tuberculosis. Am Rev Respir Dis. 1993; 148: 2- 5.
21. De Groote MA and Fang FC. NO inhibitions: antimicrobial properties of nitric oxide. Clin Inf Dis. 1995; 21 (2): S162-5.
22. Expert group meeting report. World Health Organization, Geneva; 2013: 1–31 http://www.who.int/tb/challenges/mdr/bedaquiline/en/index.html. (Accessed March 24, 2014).
23. Maes: TB chemotherapy, diagnosis, prognosis BBRJ 2019; 3 (3): 145-150.
24. Failure of Dots Pakistan https://docs.google.com/document/d/0BzOCEfOSmeiUZ183ZElFWkpRY0E/edit?usp=sharing&ouid=106232283876325533470&resourcekey=0-bMJFypsI8iIiD7UgpKKZSQ&rtpof=true&sd=true
25. Cochrane M. vaccae: de Bruyn G, Garner P. Mycobacterium vaccae immunotherapy for treating
tuberculosis The Cochrane Library (Review) The Cochrane Library 2010, Issue 1; 1-29
https://drive.google.com/file/d/1dTRjzs7jSK8P5EuuBQOhsi2kzATjFfdT/view?usp=sharing
26. Shui-Hua: Immunotherapy with M. vaccae vaccine to multidrug-resistant pulmonary TB. 30th IUATLD World Conf. on Lung Health. Madrid, 14-18 September 1999. 331-PS.
27. Federlin JD, Maes D, Maes R. Aspidosperma subincanum I. Characterization, extraction of an
uleine-enriched fraction and potential health hazard due to the contaminant ellipticine. Brazilian J. Pharmacognosy 2014;24: XX
https://drive.google.com/file/d/0B-rH5q_guaV2dGFNRnpFdHpYT2M/view?usp=sharing&resourcekey=0-aBZrZJRQ2uU200zkfngtYw
28. Uleine project Working Group on New TB Drugs STOP TB PARTNERSHIP DRUG PIPELINE
Improvement of TB drug activity with Uleine alkaloid; Last Updated: 5-Oct 2014 https://docs.google.com/document/d/0B-rH5q_guaV2TWNnZXZyVXFoQ0E/edit?usp=sharing&ouid=106232283876325533470&resourcekey=0-SfbKWdRvRxXdGQ2INWhd-w&rtpof=true&sd=true
29. Maes D, Maes R. Aspidosperma subincanum II. Usefulness of uleine and ribonucleic fragments in the treatment of AIDS patients. Rev Bras Farmacogn 2015 ; 25 :42-6
30. WHO Policy statement: Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update.2013; ISBN: 978 92 4 150633 5.
31. WHO policy Latent tuberculosis infection: updated and consolidated guidelines for programmatic management ISBN 978-92-4-155023-9 © World Health Organization 2018 ;78 pages
https://drive.google.com/file/d/1i_vhAIwRts4vSrTC-7zduULyaWYQmzGG/view?usp=sharing
32. Singh A, Gupta AK, Gopinath K, Pawan Sharma P. Singh S Evaluation of 5 Novel protein biomarkers for the rapid diagnosis of pulmonary and extra-pulmonary tuberculosis: preliminary results. www.nature.com/scientificreports 2017; 1-10
https://drive.google.com/file/d/1GEQpSpX6T6p3TNB_n3i5pT8x58ClwKQy/view?usp=sharing
33. Wirrmann C. Public health application of a serological test for tuberculosis: Study of the incidence of inapparent infections among the employees of an Alsatian supermarket. Eur J Epidemiol 1990; 6:304-8
34. Kaustová J. Serological IgG, IgM and IgA diagnosis and prognosis of mycobacterial diseases in routine practice. Eur J Med Res 1996; 1:393-403.
35. Editorial: Failing the Public Health: The Ban of Tuberculosis Serology and the WHO. BBRJ. 2018; 2 ;2: 1=7.
https://drive.google.com/file/d/1osTA8v9rwva8vcK8YCqc5LWB3l2cmsKl/view?usp=sharing
36. Chatterjee: Controlled clinical trials. Comments on the contribution of Prof. Grosset. Int. J. Lepr.
1990; 58: 376-378.
37. Grosset JH, Ji BH. Controlled clinical trial for evaluation of antimicrobial drug activity against M leprae. Int. J. Lepr. 1989; 57: 529-531.
38. Maes R. Prevention is a neglected aspect in the eradication policies against tuberculosis. J Prev
Diagn Treat Strategies Med ;2022; 1: 234-9. https://drive.google.com/file/d/1EbR53srUorgvbWbqzK8lS7LFfEC3BmNT/view?usp=sharing
39 . Rufai SB, Singh A, Kumar P, Singh J, Singh S. 2015. Performance of Xpert MTB/RIF assay in diagnosis of pleural tuberculosis by use of pleural fluid samples. J Clin Microbiol 2015; 53:3636 –3638. doi:10.1128/JCM.02182-15.
https://drive.google.com/file/d/1hixdmj09wM_HgP3Sz7FHdSAy2OlGYkCb/view?usp=sharing
40 . India’s failure
https://docs.google.com/document/d/1ey8VFY4IK2tAPdC2rFghnAnenEXUnLVR/edit?usp=sharing&ouid=106232283876325533470&rtpof=true&sd=true
41. Mingote LR, Namutamba D, Apina F, Barnabas N, Contreras C, Elnour T, et al. The use of
bedaquiline in regimens to treat drug-resistant and drug-susceptible tuberculosis: A perspective
from tuberculosis-affected communities. Lancet 2015; 385 :477-9
42. Baker M. Statisticians issue warning over misuse of P values Policy statement aims to halt
missteps in the quest for certainty. Nature .2016 ; 531,151 doi :10.1038/nature.19503
https://docs.google.com/document/d/1NXeStO-jUmycPaiHOV7gK4-KmgA4_S0q/edit?usp=sharing&ouid=106232283876325533470&rtpof=true&sd=true
43. Maes R. Tuberculosis serology is useful in rural areas. Biomed Biotechnol Res J; 2017;1-9.
https://drive.google.com/file/d/1SF_3Zvgvvj9n0mS_J0W0qN14hR6wCvea/view?usp=sharing.
44. Bugiani M. et al.: Tuberculin reactivity in BCG vaccinated subjects. 30th IUATLD World Conf.
on Lung Health. Madrid, 1999; 14-18 September 118-PD
45. Schaaf HS, Zumla A. Tuberculosis A comprehensive clinical reference. Saunders, Elsevier 2009;
1034.
https://drive.google.com/file/d/1haI2ydsPUBJbLJQRVq2ic5FQQ1SkKLOD/view?usp=sharing
46. Maes R. Clinical usefulness of serological measurements obtained by antigen 60 in mycobacterial
infections: development of a new concept. Klin. Wochenschr. 1996; 69: 696-709.